Bausch + Lomb (BLCO)
(Delayed Data from NYSE)
$15.09 USD
+0.22 (1.48%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $15.09 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$15.09 USD
+0.22 (1.48%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $15.09 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth C Momentum D VGM
Zacks News
Elevance Health (ELV) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Elevance Health (ELV) delivered earnings and revenue surprises of 2.49% and 4.48%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Novartis (NVS) Entresto Patent Faces Setback, Stock Down
by Zacks Equity Research
Novartis (NVS) faces a setback in the patent litigation with respect to the blockbuster heart disease drug Entresto. Shares decline.
BLCO or DOCS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BLCO vs. DOCS: Which Stock Is the Better Value Option?
Novartis (NVS) to Divest Xiidra, SAF312 to Streamline Focus
by Zacks Equity Research
Novartis (NVS) signs a deal to divest Xiidra and SAF312 (libvatrep) to Bausch + Lomb for $2.5 billion.
Bausch + Lomb (BLCO) Q1 Earnings Lag Estimates
by Zacks Equity Research
Bausch + Lomb (BLCO) delivered earnings and revenue surprises of -28.57% and 3.98%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Bausch + Lomb (BLCO) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Bausch + Lomb (BLCO) stock based on the movements in the options market lately.
BLCO vs. DOCS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
BLCO vs. DOCS: Which Stock Is the Better Value Option?